Filing Details
- Accession Number:
- 0001214659-18-001072
- Form Type:
- 13G Filing
- Publication Date:
- 2018-02-12 06:09:46
- Filed By:
- Bankier Alain D
- Company:
- Nexien Biopharma Inc.
- Filing Date:
- 2018-02-12
- SEC Url:
- 13G Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Alain D. Bankier S.S. OR | 2,284,000 | 0 | 2,284,000 | 0 | 2,284,000 | 5.2% |
Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment _______)*
INTIVA BIOPHARMA INC.
(Name of Issuer)
Common Stock, $0.0001 par value
(Title of Class of Securities)
46116E 103
(CUSIP Number)
December 31, 2017
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
| ☐ | Rule 13d-1(b) |
| ☐ | Rule 13d-1(c) |
| ☒ | Rule 13d-1(d) |
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 46116E 103
SCHEDULE 13G
| 1 | NAMES OF REPORTING PERSONS Alain D. Bankier S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (Entities Only) | |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) | (a) ☐ (b) ☐ |
| 3 | SEC USE ONLY | |
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION United States | |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER 2,284,000 |
| 6 | SHARED VOTING POWER 0 | |
| 7 | SOLE DISPOSITIVE POWER 2,284,000 | |
| 8 | SHARED DISPOSITIVE POWER 0 |
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,284,000 shares | |
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) | ☐ |
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.2% | |
| 12 | TYPE OF REPORTING PERSON (See Instructions) IN | |
CUSIP No. 46116E 103
Item 1(a). Name of Issuer:
Intiva BioPharma Inc.
Item 1(b). Address of Issuer’s Principal Executive Offices:
4340 East Kentucky Avenue, Suite 206,
Glendale, Colorado 80246
Item 2(a). Name of Person Filing:
Alain D. Bankier
Item 2(b). Address of Principal Business Office or, if none, Residence:
101 Central Park West
New York, New York 10023
Item 2(c). Citizenship:
United States
Item 2(d). Title of Class of Securities:
Common Stock, $0.0001 par value
Item 2(e). CUSIP Number:
46116E 103
Item 3.
Not applicable
Item 4. Ownership.
See Rows 5 through 8 of the cover pages.
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of a class of securities, check the following [ ].
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being reported on By the Parent Holding Company.
Not applicable.
CUSIP No. 46116E 103
Item 8. Identification and Classification of Members of the Group.
Not applicable.
Item 9. Notice of Dissolution of Group.
Not applicable.
Item 10. Certification.
Not applicable.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| February 9, 2018 | /s/ Alain D. Bankier |
| Alain D. Bankier |
Page 4 of 4